Skip to main content
. 2021 Sep 13;184(2):191–203. doi: 10.1093/toxsci/kfab112

Figure 2.

Figure 2.

The morphogenetic impact of dolutegravir (DTG) is not due to folic acid deficiency. A, Representative images of cell aggregates at day 4 that have been treated with DTG with or without folic acid or folinic acid at the indicated concentrations. Scale bar = 500 μm. B, Morphometric parameters of day 4 cell aggregates. Graphs show averages of relative area, relative elongation distortion index (EDI), and relative aspect ratio (AR) with error bars of 95% CI, based on measurement of 46–48 aggregates for each condition. All 3 parameters are significantly reduced in DTG-treated groups compared with the corresponding control group, as indicated with asterisks (p < .01; 2-sample t test). However, no significant difference from the DTG-treated groups was observed due to supplementation of folic acid or folinic acid.